Skip to content

Use of a Biological Mesh (StratticeTM) for the Prevention of Parastomal Hernia After Colorectal Surgery With Colostomy

Prospective, Multicenter, Randomized, Parallel Group Clinical Study Evaluating the Efficacy of a Biological Mesh (StratticeTM) for the Prevention of Parastomal Hernia After Colorectal Surgery With Colostomy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02121743
Acronym
PROBIOCOL
Enrollment
80
Registered
2014-04-23
Start date
2014-04-14
Completion date
2023-12-01
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parastomal Hernia, Terminal Colostomy

Keywords

strattice, colostomy, parastomal hernia

Brief summary

In France around 5,000 colostomies are performed after elective or emergency surgery. These colostomies could be associated with major outcomes including parastomal hernia (4 - 53%) of cases. To reduce the incidence of these outcomes, several methods have been proposed but the more pertinent consist in the use of a biological mesh during the stoma's conception. Nevertheless there is no data on the use of a biological mesh (StratticeTM) for the prevention of parastomal hernia.

Interventions

DEVICEstrattice

use of a strattice

PROCEDURENo strattice

no use of a strattice

Sponsors

LifeCell
CollaboratorINDUSTRY
Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient requiring a colorectal surgery with a terminal colostomy * Elective or emergency surgery

Exclusion criteria

* Has collagen-vascular, connective tissue, or uncorrectable bleeding disorders as determined clinically by the PI. * Has any disease, including uncontrolled diabetes, which is clinically known to impact wound healing ability. * Has an autoimmune disease, an immune deficiency, or is on immune suppression drugs * Is pregnant, or lactating. * Allergic to any porcine or collagen products. * survival \< 6 months

Design outcomes

Primary

MeasureTime frameDescription
rate of parastomal herniapostoperative month 6the presence of a parastomal hernia will be diagnosed either by the clinical examination either by a CT scan

Secondary

MeasureTime frameDescription
evaluation of the pain2 years after the surgeryThe pain will be evaluated with a visual scale 1 month, 6 months, 1 year and 2 years after the surgery
the postoperative morbiditypostoperative month 1the postoperative morbidity will be assessed with the Dindo Clavien classification
the parastomal hernia ratepostoperative year 1The parastomal hernia rate will be evaluated 1 year after the surgery during the clinical examination
the quality of life2 years after the surgeryThe quality of life will be assessed with the STOMA QoL form, the 12-Item Short Form Health Survey (SF12) and the Carolina comfort scale at 1 month, 6 months, 1 year and 2 years after the surgery

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026